Timolol

Selected regular solution, preservative-free Ocudose, gel-forming solution, Betimol and Istalol treat elevated intraocular pressure in ocular hypertension or open-angle glaucoma. Ocudose is an option when preservative-free treatment is advisable. Timolol is not adequate alone for acute angle-closure glaucoma.

The selected oral tablet label indicates hypertension; reduction of cardiovascular mortality/reinfarction risk in clinically stable survivors of the acute phase of myocardial infarction; and migraine prophylaxis. These are product-label indications, not a claim that timolol is preferred in every contemporary treatment pathway. Oral tablets are not glaucoma-drop replacements and migraine prophylaxis is not acute rescue treatment.

Current FDA records list Rising ANDA207556 oral 5, 10 and 20 mg products as prescription; this status does not guarantee supply. The retrieved current Rising label, rather than discontinued Mylan strengths, supplies the oral regimens here.

Regular solution, Ocudose and Betimol usually start with one drop of 0.25% in the affected eye(s) twice daily; if inadequate, increase to one drop of 0.5% twice daily. Once-daily administration can be considered when pressure is satisfactorily controlled, with pressure checks at different times of day. Reassess after about four weeks because response may stabilize gradually; doses above one drop of 0.5% twice daily generally add no pressure reduction.

Sagent gel-forming solution: one drop of either 0.25% or 0.5% in affected eye(s) once daily; doses above one drop of 0.5% daily are unstudied. Invert the closed bottle and shake once before use; give other ocular medicines at least 10 minutes before it. Istalol 0.5%: one drop in affected eye(s) once each morning; separate other ocular medicines by at least five minutes. Do not generalize these schedules to every timolol bottle.

Titrate using pulse, blood pressure, clinical benefit and tolerance rather than an eye-drop concentration.

Use each Ocudose unit immediately for one or both eyes and discard the remainder immediately; sterility is not assured after opening. Do not touch multidose tips to an eye or surface. Avoid abrupt withdrawal of chronic oral timolol: the oral label calls for reduction over one to two weeks with monitoring, especially with ischemic heart disease. Surgical and clonidine transitions require an individualized clinician plan.

The selected oral and ocular labels contraindicate asthma or a history of asthma, severe COPD, sinus bradycardia, second- or third-degree AV block, overt cardiac failure, cardiogenic shock and hypersensitivity to the product or its components. Do not infer that absence of wheezing today removes a history-of-asthma contraindication.

The retrieved selected oral and ocular SPLs have no boxed-warning section. Chronic oral discontinuation nevertheless carries a prominent ischemic-heart-disease warning, including supervised gradual reduction over one to two weeks; absence of a box is not absence of risk.

Ocular burning/stinging, irritation and transient blurred vision occur; gel-related blur can interfere with driving. Systemic effects include fatigue, dizziness, slow pulse, low blood pressure, conduction block, heart failure, bronchospasm, mood/sleep changes and allergy. Frequencies differ by product and trial and should not be pooled. Excess oral or ocular exposure can produce bradycardia, hypotension, bronchospasm or cardiac arrest; seek emergency and poison-center assistance.

Coordinate changes across eye and systemic treatment; do not independently stop clonidine or a beta blocker.

Adequate controlled pregnancy data are lacking; use only when expected benefit justifies potential fetal risk. Timolol is detected in human milk after oral and ocular use. Istalol’s current lactation section weighs breastfeeding benefits, maternal need and potential infant effects; older selected labels advise choosing whether to discontinue nursing or treatment because of possible serious infant reactions. Make a product-specific shared decision.

Rising regular solution, Nordic Ocudose and Sagent gel-forming labels establish pediatric use at age two and older; below two it is unestablished. Betimol and Istalol pediatric safety/efficacy are unestablished. Do not transfer these age boundaries to Betimol or Istalol. Oral pediatric use is unestablished. Selected ocular labels report no overall geriatric difference where addressed; oral geriatric dosing should start cautiously toward the low end, considering renal, hepatic and cardiac function.

Oral timolol is partially metabolized by the liver and mainly excreted through the kidneys; reductions may be necessary with renal or hepatic insufficiency, but the label provides no fixed numerical adjustment formula. Marked renal failure on dialysis has produced substantial hypotension after 20 mg oral doses: be especially cautious. Selected ocular labels provide no separate numerical renal/hepatic regimen. Dialysis did not readily remove timolol in a renal-failure study despite in-vitro dialyzability.

Timolol blocks beta-1 and beta-2 receptors without significant intrinsic sympathomimetic activity. Ocular pressure reduction is attributed principally to reduced aqueous formation, although the precise mechanism is incompletely established. Systemic blockade reduces cardiac output and can increase airway resistance. Ocular onset may occur within half an hour, with peak effect at one to two hours and persistence up to 24 hours.

Oral absorption is approximately 90%, with peak concentrations at one to two hours and a plasma half-life around four hours. First-pass metabolism reduces systemic availability; hepatic metabolism and renal excretion contribute to disposition. Do not pool ocular exposure across vehicles: regular 0.5% twice-daily solution produced mean morning peak 0.46 ng/mL in six subjects, whereas Istalol’s 12-subject exaggerated twice-daily study measured 0.68 and 0.88 ng/mL at two hours on days one and eight. These studies do not establish a universal eye-drop bioavailability or conversion to oral dose.

Reassess intraocular pressure at about four weeks and across the day when changing regular products to once daily. Monitor pulse, blood pressure, breathing, heart-failure symptoms and dizziness. With oral therapy assess indication-specific response and renal function when appropriate; monitor glucose independently of masked adrenergic symptoms. Consider alternative therapy for reduced cerebral perfusion signs.

Do not contaminate the tip; ask the eye clinician about continued use after eye trauma, infection or surgery. Regular Rising solution and Istalol contain benzalkonium chloride: remove soft contact lenses and wait 15 minutes before reinsertion. Betimol separates other drops by at least five minutes; gel-forming solution requires other medicines at least 10 minutes before it and one inversion/shake. Ocudose has immediate single-use discard instructions. Seek urgent advice for wheeze, fainting, very slow pulse or new swelling/shortness of breath.

Discuss slow pulse, dizziness, fatigue, mood changes and impaired exercise tolerance. Do not interrupt chronic oral therapy without a planned taper and monitoring. Tell the anesthesia team about oral and ocular use; a decision to withdraw before surgery is individualized. Migraine treatment is preventive, and lack of benefit at the maximum tolerated labeled regimen should trigger reassessment.

Rising timolol maleate ophthalmic solution 0.5%: clear colorless sterile solution, translucent LDPE bottle with yellow cap; selected 5 mL bottle NDC 64980-514-05. This identifier illustrates a verified label and does not confirm commercial stock.

Regular maleate solution, Ocudose units and selected gel-forming solution contain 0.25% or 0.5% timolol equivalent. Ocudose units contain 0.3 mL. Betimol hemihydrate solution is 0.25% or 0.5%; Istalol maleate solution is 0.5% (5 mg/mL timolol). Selected oral tablets contain 5, 10 or 20 mg timolol maleate; these are not interchangeable with an ophthalmic milligram concentration. Fixed combinations with dorzolamide or brimonidine are outside this standalone profile.

Rising regular solution, Sagent gel, Betimol and Istalol: 15–25°C; regular solution/gel/Betimol require light protection and no freezing. Regular solution and Istalol may be used until labeled expiration after opening. Ocudose: 15–30°C, no freezing/light protection; keep units in foil and use within one month after opening the foil, with each opened vial used immediately and discarded. Oral tablets: 20–25°C, protect from light, dispense in tight light-resistant child-resistant container. Follow the dispensed manufacturer’s instructions.